Loading
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
NASDAQConsumer CyclicalAuto - Parts
Latest quote
$8.30
$0.00 · 0.00%
Previous close
$8.30
$0.00 · 0.00%
Regular session · ET · Market data may be delayed.
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Day range
Current $8.30
52-week range
Current $8.30
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
60
Fair Value
Sentiment
51
Mixed
Risk
57
Elevated Risk
Momentum
56
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Day range
Current $8.30
52-week range
Current $8.30
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.2K USD | — | — | — | — |
| Cost of goods sold | 6.32K USD | — | — | — | — |
| Gross profit | −116 USD | — | — | — | — |
| Research and development | 923.91K USD | 144.36K USD | 72.05K USD | — | — |
| Selling, general, and administrative | 18.43M USD | 1.07M USD | 1.34M USD | 976.35K USD | 27.79K USD |
| Operating expenses | 19.35M USD | 1.21M USD | 1.34M USD | 976.35K USD | 25.48K USD |
| Interest income | — | 548.68K USD | 5.81M USD | 4.32M USD | — |
| Interest expense | 8.53M USD | 97.99K USD | 8.97K USD | — | — |
| Depreciation and amortization | 8.02M USD | — | 1.34M USD | — | 27.79K USD |
| Operating income | −19.35M USD | −1.21M USD | −1.34M USD | −976.35K USD | −25.48K USD |
| Net income | −24.48M USD | −1.31M USD | 4.46M USD | 3.34M USD | −25.48K USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 11, 2026 | 1:30 | — | — |
Stock split | Jan 16, 2026 | 1:40 | — | — |
Effective May 11, 2026
1:30
Effective Jan 16, 2026
1:40
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
